@UrogerliMD Profile picture

Roger Li

@UrogerliMD

Urologic oncologist @MoffittNews | Translational researcher | Views are my own

Similar User
Sarah P. Psutka MD MS photo

@spsutkaMD

Peter Black photo

@pcvblack

Sia Daneshmand, M.D. photo

@siadaneshmand

YUO photo

@SUO_YUO

Surena F Matin MD photo

@SurenaMatinMD

Stephen Boorjian, MD photo

@SBoorjian

Piyush Kumar Agarwal photo

@Agarwal_CaB

Sam S. Chang MD, MBA photo

@UroCancerMD

Wade J Sexton photo

@WadeJSexton9

Scott Gilbert photo

@sgilbert1973

Logan Zemp photo

@LoganZemp

Jim Hu photo

@jimhumd

Philippe spiess photo

@SpiessPhilippe

Bernie Bochner, MD photo

@bbmdmsk

Jay Raman photo

@urojdr

Pinned

Excited to open the combination neoadjuvant trial combining IVe oncolytic virus #CG0070 and nivo in cis-ineligible patients with #MIBC @MoffittNews Looking forward to pursuing translational research looking for potential synergism in this combo moffitt.org/endeavor/archi…


Roger Li Reposted

@UrogerliMD calls it “a promising strategy with a favorable safety profile.” This innovative therapy could be a game-changer for those who need alternatives to traditional chemo. #MoffittAmbassador x.com/MoffittNews/st…


Roger Li Reposted

Join us in congratulating our President and CEO, @PatrickHwuMD, for being selected for the 2024 @FloridaTrend edition of the Florida 500! The special publication highlights the 500 most influential executives in different economic sectors throughout the state. We are so lucky to…

Tweet Image 1

Roger Li Reposted

Comprehensive review of UTUC surgical management chemoprophaxis and surveillance by @BasileG_ @SpiessPhilippe @GTumors @BandiniMd @UrogerliMD journals.lww.com/co-urology/abs…


Roger Li Reposted

We would like to inform you that your post has been published on @Oncodaily Thank you for sharing! oncodaily.com/opinion/183394


Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC urologytimes.com/view/cretostim… via @@urologytimes


Roger Li Reposted

Presented at #SITC2024: In a phase 1b trial, treatment of patients with muscle-invasive #BladderCancer with intravesical #OncolyticVirus cretostimogene grenadenorepvec in combination with #Nivolumab was safe and led to encouraging preliminary clinical response rates, by…


Roger Li Reposted

While at #SITC24, Roger Li, MD (@UrogerliMD) joined me to discuss his study evaluating the use of combination oncolytic virotherapy and immune checkpoint inhibitor nivolumab to treat muscle-invasive #BladderCancer. Check out our video below 👇 and read more about his work here-…


Loading...

Something went wrong.


Something went wrong.